series-a
Stage
2
Investors
About
IGYXOS develops monoclonal antibody therapeutics that enhance the activity of Follicle Stimulating Hormone (FSH) to improve reproductive health outcomes and treat infertility in men and women.
Explore IGYXOS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.